Assessing Cancer Patients’ Tobacco Use: A New Tool Developed by the AACR and the National Cancer Institute

Researchers have well established that smoking leads to adverse outcomes in cancer patients; however, the specific effects caused by smoking and the use of other tobacco products remain poorly understood …

Read More

Overcoming Drug Resistance: The EGFR Enigma

Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, and colorectal cancer. Most patients receiving anti-EGFR therapies benefit from the treatment, but the challenge they face, as do patients receiving most other targeted therapies, is that their tumors ultimately develop drug resistance. So efforts are underway to develop newer anti-EGFR therapies that can circumvent resistance to existing EGFR inhibitors.

Read More

Eric Rubin, MD, Discusses How the AACR Contributes to Advances for Patients

AACR membership includes scientists and physicians from across the cancer research enterprise. Whether basic, translational, or clinical researchers, they all share the same goal: to make progress for patients. In this post, Eric Rubin, MD, deputy editor of Clinical Cancer Research, one of the AACR’s eight journals, shares his thoughts on the AACR’s role in developing breakthrough cancer treatments.

Read More

Kenneth C. Anderson, MD, Discusses How the AACR Benefits Clinicians

Over the years, clinical research has become an integral part of the American Association for Cancer Research’s meetings and journals. We asked physician-scientist Kenneth C. Anderson, MD, editor-in-chief of Clinical Cancer Research, one of the AACR’s eight journals, to share what the AACR means to him, where the organization is going, and why clinicians like him should be involved.

Read More

Mastering the Clinical Development of Personalized Cancer Medicines

A string of innovative clinical trials designed to accelerate the pace at which personalized cancer medicines are developed have been announced, and in some cases initiated, over the past few …

Read More